How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised
Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...
Gilead outlines 2025 sales guidance with lenacapavir launch and HIV focus
Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...
Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising.
Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.